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Introduction
Gastrointestinal stromal tumors (GISTs) are mes-
enchymal tumors of the gastrointestinal tract that are
believed to originate from a neoplastic transformation
of the intestinal pacemaker cells (interstitial cells of Ca-
jal) normally found in the bowel wall, or their precur-
sors1,2. The identification of these tumors has been facil-
itated by the recent application of CD117 immunohisto-
chemistry which identifies the c-kit proto-oncogene
product, overexpressed in nearly all GISTs, and distin-
guishes this type of neoplasm from leiomyomas or
leiomyosarcomas.
Although relatively rare, GISTs, make up the largest
subset of mesenchymal tumors of the gastrointestinal
tract and are reported to comprise about 5% of all sar-
comas3-5. The estimated annual incidence is 10-20 cases
per million, of which 20-30% are malignant, although,
following the recent clearer definition of the diagnostic
criteria for GISTs, it may be necessary to revise these
estimates6,7.
GISTs occur in both sexes with similar frequency, but
several reported data have shown a preponderance in
males, generally after the 4th decade, with most studies
finding a mean age at diagnosis of about 60 years. They
are occasionally found in young adults, although ex-
tremely rarely in children6,8. 
Such tumors may occur anywhere in the gastrointesti-
nal tract but are most commonly found in the stomach
(40-70%) and small intestine (20-40%). Only 5-15%
are found in the colon and rectum, about 5% in the
esophagus and in the omentum, and rarely in the
mesentery or retroperitoneum3,6,7,9-11.
The most common symptoms reported are vague up-
per abdominal pain, gastrointestinal hemorrhage due to
tumor bleeding, at times associated with anemia, and
the presence of an abdominal mass. GISTs may also
cause altered bowel function, bowel obstruction or per-
foration, dysphagia, and fever. 
The clinical prediagnostic workup of GISTs is the
same as for other gastrointestinal malignant disorders,
although many small GISTs are discovered by chance
during endoscopy or laparotomy performed for other
reasons, such as submucosal or subserosal nodules, or
during imaging examinations.
Surgery has been and continues to be the treatment
of choice for GISTs. The tumor may present with a
pseudocapsule and should be removed en bloc without
a wide resection margin. Regional lymphadenectomy
should be avoided since GISTs seldom spread to the
lymph nodes12-14. There are no data to support the use
of radiotherapy, and no effective chemotherapy for
GISTs existed until the introduction of imatinib mesy-
late, a potent inhibitor of two cell-surface protein tyro-
sine kinases, the platelet-derived growth factor receptor
and the stemcell factor receptor (c-kit). Activation of
c-kit, often in association with mutation of the c-kit
proto-oncogene, is believed to be present in all cases of
GISTs. High rates of objective response have been
achieved in phase I and phase II studies of imatinib thera-
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py for such tumors at a recommended dose of 400 mg
per os daily.
Patients and methods
Nine patients affected by GISTs were observed in our
Institute between April 2002 and July 2004. A GIST
was defined as a mesenchymal tumor with immunohis-
tochemical positivity for CD 117, the proto-oncogene
protein of c-kit. In addition, immunohistochemical stag-
ing for CD34, desmin and the S100 protein was per-
formed, and tumor resection margins and tumor histo-
logical subtype were determined. Tumors were consid-
ered malignant if they had more than five mitoses per
50 high power fields (>5 x 50/HPF).
Staging and therapeutic choices were based on CT of
the abdomen and, in all the cases with gastric GISTs, on
endoscopy for biopsy specimens and echoendoscopy. 
For patients undergoing surgery, resection was con-
sidered complete if all gross disease was resected at the
initial exploratory procedure with reported negative
margins. The level of response to treatment with ima-
tinib mesylate was evaluated on the basis of radiologi-
cal measurement of the tumor. Radiographic tumor size
was defined as the length in centimetres of the greatest
diameter, according to the RECIST criteria. A complete
radiographic response was defined as a failure to identi-
fy a lesion that had been present on previous radi-
ographic images. 
Results
Between April 2002 and July 2004, 9 patients, 4 men
and 5 women, affected by GISTs were observed in our
Institute. Mean age was 64.5 years (range, 51-75). Eight
tumors were in the gastric area and 1 was in the small
bowel. 
In 5 cases, 4 of the gastric GISTs and the small bowel
tumor, complete surgical removal was performed. Of
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the 4 gastric GISTs, partial gastrectomy according to
Billroth II was performed in 1 case. In the other 3 pa-
tients, a partial wedge gastrectomy was performed, one
under videolaparoscopic control. In the remaining
GISTs, small bowel resection was performed on the in-
volved ansa. None of these 5 patients underwent adju-
vant therapy with imatinib mesylate; so far, none of
them has shown disease relapse (Table 1).
Of the 4 patients treated with imatinib mesylate, 2
presented local recurrence and the other 2 showed
metastatic disease from the beginning. The 2 cases with
localregional relapse were successfully treated with
imatinib mesylate and then with radical surgery. Both
patients are still alive and show no signs or symptoms
of the disease. The 2 cases with metastatic disease un-
derwent imatinib therapy. In only one of these patients
was it possible to make an evaluation; he did not re-
spond to a dose of 400 mg of imatinib but obtained CR
with 800 mg. The second patient was not assessable be-
cause he had no measurable disease. The treatment was
well tolerated, giving rise only to slight nausea and pe-
riorbital edema (Table 2).
Discussion
GISTs are the most common mesenchymal neoplasm
affecting the gastrointestinal tract. The term GIST was
first used by Mazur and Clark in 1983 to describe gas-
trointestinal non-epithelial neoplasms with neither the
immunohistochemical features of Schwann cells nor the
ultrastructural characteristics of smooth-muscle cells.
The discovery of gain-of-function mutations in the c-kit
proto-oncogene in GISTs by Hirota and colleagues in
1998 was of crucial importance in terms of the genesis
and classification of these tumors15. This finding led to
the development of rational molecularly targeted thera-
py of GISTs with the kit-receptor tyrosine-kinase in-
hibitor, imatinib mesylate (formerly known as STI571).
With the identification of the tyrosine kinase inhibitor
Table 1 - Characteristic of the 5 cases treated by surgery alone
Sex Age (yr) Localization Size (cm) Mitotic index Surgical procedure Follow-up (mo) Relapse
M 65 Stomach 8 <5 x 50/HPF Partial gastrectomy, Billroth II 38 No
F 66 Stomach 17 >5 x 50/HPF Partial gastric wedge resection 36 No
M 73 Small bowel 20 <5 x 50/HPF Small bowel resection 30 No
F 75 Stomach 4 <5 x 50/HPF Partial gastric wedge resection VLS 24 No
M 75 Stomach 8 <5 x 50/HPF Partial gastric wedge resection 10 No
Table 2 - Characteristic of the 4 cases treated with imatinib mesylate
Sex Age (yr) Localization Mitotic index Dose of Response Follow-up (mo) Surgery after  Relapse
imatinib/day response to imatinib
F 64 Stomach >5 x 50/HPF 400 PR, then surgery 57 Yes NED
F 56 Stomach >5 x 50/HPF 400 PR, then surgery 51 Yes NED
M 51 Stomach, liver <5 x 50/HPF 400-800 CR at 800 mg 45 No NED
F 61 Stomach, liver, <5 x 50/HPF 400 NE 6 Not applicable NE
peritoneum
PR, partial response; CR, complete response; NE, not evaluable; NED, no evidence of disease.
imatinib mesylate as an effective therapeutic agent, it
has become increasingly important in the clinical treat-
ment of GISTs to distinguish these neoplasms from oth-
er mesenchymal tumors such as leiomyomas,
leiomyosarcomas, and schwannomas. 
At present, GISTs are defined as spindle-cell, epithe-
lioid, or occasionally pleiomorphic mesenchymal tumors
of the gastrointestinal tract that express the kit protein6,7.
The kit protein is often detected clinically by immuno-
histochemical assays for the CD117 antigen, an epitope
of the kit-receptor tyrosine kinase. GISTs characteristi-
cally stain strongly for the CD117 antigen, whereas
smooth-muscle neoplasms (leiomyoma and leiomyosar-
coma), neurogenic tumors (schwannomas), and desmoid
fibromatoses typically do not show this positive expres-
sion of CD1176,7,11. In addition to CD117, GISTs com-
monly exhibit positive staining for CD34, a sialylated
transmembrane glycoprotein, but less commonly for
SMA and S100 (neural cell marker), which are ex-
pressed typically by leiomyosarcomas and schwanno-
mas, respectively7,16. Thus, CD117 immunostaining is an
important method for diagnostic distinction.
There is no consensus within surgical and pathologi-
cal communities regarding the grading or classification
of GISTs. Malignant potential is not always predicted
by conventional histologic factors. Because of this,
some investigators have suggested that the terms benign
and malignant GIST be replaced by low, intermediate,
or high risk for malignant behavior17,18. Several factors
independently predict the prognosis of GISTs following
resection. The most important and easily applicable his-
tologic criteria for prediction are tumor size (maximum
diameter in cm), and mitotic rate11,18-20. A rate of ≤5 mi-
toses per 50 HPF is commonly used as a limit for a tu-
mor of expected benign behavior, and according to a
large study, this can discriminate between benign and
malignant gastric tumors, but not between benign and
malignant small intestinal tumors11. Low-grade tumors
(mitotic index <10 per 50 HPF) also lead to a better
outcome than high-grade tumors (mitotic index >10 per
50 HPF). Tumors of 2 cm in diameter are generally ex-
pected to behave in a benign fashion. Tumors of <5 cm
in diameter are associated with a better survival rate
than those of 5-10 cm, which in turn have a better prog-
nosis than those of >10 cm. Degree of cellularity and
atypia have also been suggested as useful criteria, but
their reproducibility is more problematic. Finally,
GISTs found in the stomach are associated with better
survival than those located in the small intestine. Limit-
ed survival information is available for GISTs found in
other locations. Age has also been suggested as an inde-
pendent prognostic factor, but studies published up till
now have not reported figures regarding cancer deaths9.
Many others factors have also been investigated. Kary-
otypic or genetic markers such as deletions in chromo-
some 9p21 or gain of function mutations in exon 11 of
the c-kit gene have been correlated with malignant be-
havior in some studies22-25 but still require further vali-
dation.
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A peculiar feature of GISTs is that most recurrences
are solely intra-abdominal. Macroscopic extra-abdomi-
nal metastases are uncommon even in advanced dis-
ease, and they rarely occur in the absence of intra-ab-
dominal relapse. This feature contrasts with true
leiomyosarcomas of the abdomen and gastrointestinal
tract, which commonly give rise to pulmonary metas-
tases8,15. About 40-80% of GISTs recur despite
histopathologically complete tumor resection. Most re-
currences take place within 5 years of the primary diag-
nosis9, but in the slowly proliferating subset of GISTs,
metastases may appear more than 10 years after the pri-
mary diagnosis. The most common sites of metastases
are the peritoneum and the liver3,8, whereas regional
lymph node metastases are extremely rare3,13. In one re-
view of 60 patients with recurrent GISTs, local recur-
rence occurred in 76% of patients, half of whom had
synchronous liver metastases, 15% liver metastases,
and 7% peritoneal metastases26. None had extra-abdom-
inal metastases at the first relapse. Peritoneal metastases
are most probably a result of tumor cell seeding from
the primary tumor directly into the peritoneal cavity.
Similarly, liver metastases most probably result from
hematogenous seeding into the portal vein. 
The clinical presentations of GISTs are highly vari-
able according to their site and size. Many small GISTs
are discovered incidentally during endoscopy or laparo-
tomy performed for other reasons such as submucosal
or subserosal nodules, or during imaging examinations.
Symptomatic GISTs are usually larger in size. At pre-
sentation, the most common symptoms of GISTs are
vague abdominal discomfort or pain, presence of a pal-
pable abdominal mass, feeling of abdominal fullness,
and secondary symptoms resulting from tumor bleeding
and associated anemia. GISTs can also cause altered
bowel function, bowel obstruction or perforation, dys-
phagia, and fever. Duodenal GISTs occasionally cause
obstructive jaundice. GISTs are commonly discovered
during emergency surgery for sudden perforation of the
gastrointestinal tract and consequent intra-abdominal
blood loss27, and 15-50% of GISTs present with overtly
metastatic disease3,20,28. 
Nevertheless, the most common symptoms seem to
be gastrointestinal bleeding (20-50%) and vague upper
abdominal pain/dyspepsia (50-70%)3,25,29-31. In a series
of 55 patients evaluated at the Massachusetts General
Hospital, for example, gastrointestinal bleeding and
pain/dyspepsia were found in 26% and 14% of patients,
respectively32. In the study, fewer than 10% had a pal-
pable mass or perforation, and obstruction was only
found in 3% of patients. However, in a series of 200 pa-
tients evaluated at the Sloan-Kettering Memorial Can-
cer Center, most patients presented with gastrointestinal
bleeding3. 
In rare instances, GISTs occur as part of tumor syn-
dromes. Carney’s triad, described by the endocrine
pathologist J. Aidan Carney of the Mayo Clinic, in-
cludes gastric GIST, paraganglioma and pulmonary
chondroma (by definition, at least two of these tumors
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seen in the same patient). Familial occurrence has been
suggested for Carney’s triad, but no detailed molecular
genetic mechanism is known33. A pathogenetic correla-
tion has also been suggested between neurofibromatosis
type 1 (von Recklinhausen’s disease) and GISTs be-
cause of the high frequency of non-random association
of these diseases34. However, most GISTs are sporadic,
and predisposing factors are unknown.
Radiological investigations occasionally pick up inci-
dental cases. Imaging features usually offer information
valuable to distinguish tumors of mesenchymal origin
from lymphoma and epithelial neoplasms of the gas-
trointestinal tract. Nevertheless, the further differentia-
tion of mesenchymal gastrointestinal neoplasms re-
quires histological and immunochemical tests. Attempts
to predict potential malignant behavior of GISTs from
their imaging features have been unsuccessful. Image-
guided tissue biopsy is also occasionally performed for
selected cases.
Surgery remains the standard treatment for non-
metastatic GISTs. As with other soft-tissue sarcomas, a
true capsule does not exist, and the tumor should be re-
moved en bloc with its pseudocapsule and, if possible,
an adjacent margin of normal soft tissue or bowel, even
though the optimum width of the tumor-free margin has
still to be defined. In cases where contiguous organs are
involved, en bloc resection has been recommended
wherever feasible35. Local peritoneal tumor seeding is
common, and a local peritonectomy should be per-
formed if possible. Regional lymphadenectomy should
be avoided since GISTs seldom spread to lymph
nodes13,14. Tumor rupture, spontaneously or during
surgery, may be associated with an increased risk of de-
velopment of peritoneal implants and should be
avoided36. 
Up to the year 2000, studies of GISTs included tu-
mors that would not at that time have been classified as
GISTs and data are therefore contaminated by these cas-
es. However, the overall survival rates at 5 years range
from 40% to 65% after complete resection3,28,36-41, ver-
sus a median survival of 9-12 months for incomplete re-
section32,39.
In two recent large series of malignant GISTs pre-
senting combined data on 200 tumors from the Sloan-
Kettering Memorial Cancer Center3 and 191 tumors
from the MD Anderson Cancer Center36, overall 5-year
survival was 35% and 28%, respectively. However,
these patients, seen in two large oncologic hospitals, in-
cluded many subjects referred for local failure or metas-
tasis. The 5-year actuarial disease-free survival was
much better, at 54% for patients whose tumors were
completely resected13. 
Five-year survival after complete surgical resection
varies considerably in published series involving pa-
tients with GISTs, as shown in Table 33,36,39-41. 
There are still insufficient data about the usefulness
of resecting recurrent disease or intra-abdominal metas-
tases. In some studies, tumor-specific mortality and
overall survival have not differed significantly between
patients who underwent complete resection of recurrent
disease and those who had partial resection or biopsy
alone26. However, there is evidence that metastasectomy
may improve survival in selected patients. Patients with
well or moderately differentiated GISTs, with a disease-
free interval between the diagnosis and detection of
metastases of longer than 12 months, and isolated re-
sectable liver metastases are more likely to benefit from
metastasectomy than patients who have rapidly pro-
gressing or widespread GISTs42,43.
Until not long ago, the treatment for GISTs relied on
surgical resection as the only therapeutic approach. In
fact, conventional chemotherapy and external beam ra-
diotherapy have not been successful in the past in the
treatment of either recurrent or metastatic disease be-
cause of the chemoresistance of GISTs and limited radi-
ation tolerance of intra-abdominal organs. The response
rates to chemotherapy, including dacarbazine, mito-
mycin C, doxorubicin, and cisplatin, were less than
10%44-46. These chemotherapeutic strategies resulted in
partial response rates of 0% to 15% and overall survival
rates of 40% at 5 years. The introduction of imatinib-
targeted therapy for KIT that expressed GISTs has sub-
stantially impacted the clinical treatment and prognosis
of metastatic GISTs and has potentially influenced the
role of surgery.
Imatinib mesylate is a competitive inhibitor of certain
tyrosine kinases including the intracellular kinases ABL
and BCR-ABL fusion protein present in some
leukemias, kit, and the platelet-derived growth factor
receptors47. Early reports indicate that this represents
the first systemic therapy for GISTs with promising evi-
dence of treatment response48-50. 
The first case report on the effect of imatinib mesy-
late therapy for GISTs was published by Joensuu et
al.48 The patient was reported to have a significant re-
sponse to therapy, demonstrated by MRI and PET scan-
ning as well as repeated fine-needle aspiration cytol-
ogy. Subsequent series from the US-Finland GIST
Study Group and the EORTC Soft Tissue and Bone
Sarcoma Group evaluating the treatment response of
metastatic GISTs to imatinib mesylate reported partial
response rates of 59% and 69% based on radiographic
Table 3 - Five-year survival of patients with GISTs following
surgical resection
No. of patients No. of patients 5-year 
evaluated completely resected survival %
Akwari et al.41 108 52 50
Mayo Clinic
Shiu et al.40 38 20 65
MSKCC
McGrath et al.39 51 30 63
MCV
Ng et al.36 191 99 48
MDACC
DeMatteo et al.3 200 80 54
MSKCC
MSKCC, Sloan-Kettering Memorial Cancer Center; MCV, Medical Col-
lege of Virginia; MDACC, MD Anderson Cancer Center.
 
evaluation, in 86 and 36 patients, respectively46,48,51.
Recent studies have confirmed the safety of 400 mg
imatinib and the possibility of increasing the dose to
800 mg die if no response is obtained52,53. The most
common side effects were anemia (92%), periorbital
edema (84%), skin rashes (69%), and fatigue
(76%)54,55. Some authors have outlined the relationship
between molecular profile (mutations in codon 11) and
better response to treatment with imatinib56. This was
consistent with our results. Recently, a new tyrosine ki-
nase inhibitor, SU11248, seems to achieve particular
acivity in GISTs resistant to imatinib57. The role for
imatinib mesylate in the neoadjuvant and adjuvant set-
ting in the treatment for GISTs is still, however, to be
fully investigated. Two trials are currently underway to
explore the use of imatinib mesylate as an adjuvant
therapy after complete primary tumor resection
(ACOSOG Z9000 and Z9001). Trials investigating the
use of imatinib mesylate in the neoadjuvant setting are
currently in the formulative stages58. In our experience,
the 2 cases undergoing surgery after a satisfactory re-
sponse to imatinib are still alive and with no evidence
of disease relapse.
In conclusion, it is important to distinguish GISTs
from other mesenchymal tumors of the gastrointestinal
tract because of differences in biologic behavior and
treatment strategies. At present, surgery remains the
standard treatment for nonmetastatic GISTs, whereas
imatinib mesylate represents a major breakthrough in
the treatment of advanced GISTs and is the first effec-
tive systemic therapy for the disease. Nevertheless, ow-
ing to the lack of long-term data, widespread use of
imatinib mesylate outside approved indications or con-
trolled trials must be avoided. Patients with GISTs
should be considered for enrollment in one of the many
ongoing clinical trials.
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